Clinical Trial Update: An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) [Phase 3]

View source ↗

Summary

This is an open-label Phase 3 long-term study assessing safety, tolerability, and efficacy of KarXT in adult patients with schizophrenia; the trial is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-09-17